FDA Inspection 1333164 — HANSA BIOPHARMA AB
The FDA completed an inspection of HANSA BIOPHARMA AB on Aug 7, 2026 in Lund. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Aug 7, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Lund (Sweden)
Additional Details
Sponsor, Contract Research Organization